⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for chemokine antagonist

Every month we try and update this database with for chemokine antagonist cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)NCT06149481
Metastatic Colo...
Retifanlimab
Therapeutic CEA...
N-803
SX-682
18 Years - 120 YearsNational Institutes of Health Clinical Center (CC)
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)NCT06149481
Metastatic Colo...
Retifanlimab
Therapeutic CEA...
N-803
SX-682
18 Years - 120 YearsNational Institutes of Health Clinical Center (CC)
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)NCT06149481
Metastatic Colo...
Retifanlimab
Therapeutic CEA...
N-803
SX-682
18 Years - 120 YearsNational Institutes of Health Clinical Center (CC)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: